Wednesday, July 8, 2026

pharma · Rectal Cancer · Fanconi Anemia · RCKT

Rocket Pharmaceuticals

Rocket Pharmaceuticals clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

9 Cedarbrook Dr, Cranbury, New Jersey 08512, US HQ
2015 Founded
226 Employees
Public company Type
RCKT · NYSE Ticker
Company details
Status
Public
HQ
9 Cedarbrook Dr, Cranbury, New Jersey 08512, US
Founded
2015
Employees
226
Programs
11
Drugs
10
Patents
1
Intelligence · Clinical Programs

Rocket Pharmaceuticals projects

4 ClinicalTrials.gov programs sponsored by Rocket Pharmaceuticals.

Rocket Pharmaceuticals has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. RP-A501

    Rocket Pharmaceuticals B.V.

    Danon Disease

    phase 2 gene therapy active

    2 trials
  2. RP-L102

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia Complementation Group A

    phase 2 mab active

    3 trials
  3. RP-L201

    Rocket Pharmaceuticals B.V.

    Leukocyte Adhesion Defect - Type I

    phase 2 mab completed

    2 trials
  4. RP-L301

    Rocket Pharmaceuticals B.V.

    Pyruvate Kinase Deficiency

    phase 2 mab on hold

    2 trials

Frequently asked questions

How many clinical projects does Rocket Pharmaceuticals have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.